论文部分内容阅读
自1983年起,在食管癌高发区河南林县河顺乡和安阳县磊口乡,进行食管癌前病变的阻断性治疗研究。通过食管细胞学普查,检出食管上皮重增患者2531人,随机分为三组,分别服用抗癌乙片、维胺酯和安慰剂。检出轻增3393人,随机分为两组,分别服用核黄素和安慰剂。三年和五年内患者的服药率在90％以上。服药三年和五年后,进行了食管细胞学复查。结果证明,抗癌乙片和维胺酯在三至五年内,使重增的癌变率下降了50％左右。食管癌前病变的药物阻断性治疗是一条有希望的食管癌预防途径。
Since 1983, hepatic esophageal precancerous lesions have been studied in Heshun Township, Lin County, Henan Province and Leikou Township, Anyang County, a high-risk area of esophageal cancer. Through esophageal cytology survey, 2531 patients with recurrent esophageal hyperplasia were detected and randomly divided into three groups, taking anti-cancer tablets, vitamide and placebo, respectively. A surge of 3393 persons was detected and randomly divided into two groups, taking riboflavin and placebo, respectively. The patient’s medication rate is more than 90% in three years and five years. Three and five years after taking the drug, a review of esophageal cytology was performed. The results showed that the anti-cancer tablets and vitamide reduced the re-increase rate by about 50% within three to five years. Drug-blocking treatment of esophageal precancerous lesions is a promising approach for the prevention of esophageal cancer.